Liquid Dosage
With diabetes on the rise and the global insulin market estimated to be worth more than $32 billion by 2018, demand for GEA technologies for the production of this life-saving drug is already high and set to increase, particularly in new markets and emerging economies.
GEA produces and supplies process systems for the production of liquid products for the pharmaceutical and biotechnological industries, and has a proven history of successfully installing plant for the production of insulin, including the engineering, delivery, commissioning and qualification of entire ultra-pure media systems as well as various process equipment and cleaning installations.
A worldwide technology leader in insulin production, GEA is able to supply the clean utility systems and manage the integration of all the main processes, including fermentation, harvesting, chromatography, filtration and freeze drying.
The biosynthetic production of human insulin is done using bacteria or yeast cells. Following fermentation, or the conversion of chemical raw materials by micro-organisms, the biomass is extracted using a nozzle separator, washed, concentrated and finally precipitated to produce insulin crystals.
Centrifuges and process lines provided by GEA have an established pedigree in the clarification, separation, classification, concentration and fractionation steps. Nozzle separators also play an important part in the production process. Further, GEA chamber or self-cleaning separators can be used in the subsequent crystallization stages.
GEA is a single-source supplier of a variety of fermenters, media preparation, buffer storage, harvesting and cell rupture solutions, equipment for the purification and isolation of cells, separation (after both first and final crystallization), the production and distribution of WFI, CIP and freeze drying technologies, all of which can be installed and integrated into a state-of-the-art insulin production facility.
يتم عرض 4 من 14
Aseptic valves face exceptionally high demands within UltraClean and Aseptic processes. You can be assured that they all provide highest quality in terms of hygienic design and sustainability.
GEA Hilge offers a versatile range of centrifugal and positive displacement pumps for a wide variety of sensitive applications in the beverage, food and pharmaceutical industries.
GEA's thorough understanding of the lyophilization process enables them to supply a comprehensive range of products and services, comprising laboratory equipment, pilot plants for research and small-scale production batches, industrial size pharmaceutical production freeze dryers.
GEA's versatile range of R&D drying & particle processing equipment - for advanced powder processing within food and dairy products, chemicals and pharmaceuticals.
كان خبراء البحث والتطوير في GEA على قدر التحدي عندما طرحت Pulmuone، وهي شركة كورية جنوبية متخصصة في إنتاج الأغذية النباتية، تحديًا لـ GEA يتمثل في إضفاء لمسة حديثة على النودلز الكورية الباردة التقليدية ذات القوام الواضح في الفم (النينجميون). وساعدوا في تطوير ما أصبح الآن نجاحًا تجاريًا يتم إنتاجه باستخدام كميات أقل من المياه والكهرباء مقارنةً بالطرق المستخدمة سابقًا. وتتوافق النتيجة أيضًا مع الأصول التقليدية للطبق بالإضافة إلى جذور Pulmuone في الصحة والعافية والاستدامة.
تشكل عمليات GEA المبتكرة علامة فارقة في المعالجة المسبقة للوقود الحيوي مثل الزيت النباتي المعالج بالهيدروجين ووقود الطيران المستدام. من خلال التخلص من عملية التبييض، تستفيد الشركات المصنعة من إمكانات توفير كبيرة: تكاليف تشغيل أقل بنسبة تزيد عن 50% وانبعاثات أقل من ثاني أكسيد الكربون بنسبة تصل إلى 12%.